John D. Dobak
Founder chez JAKK Group, Inc.
Fortune : 490 482 $ au 31/03/2024
Profil
John D.
Dobak is the founder of Post-Hypothermia Corp.
(founded in 1998), CryoCor, Inc. (founded in 2000), Leptos Biomedical, Inc. (founded in 1992), and Neothetics, Inc. (founded in 2007).
He held the title of Consultant at Post-Hypothermia Corp., Chief Executive Officer at CryoCor, Inc., Chief Executive Officer at Leptos Biomedical, Inc., and Director at Neothetics, Inc. Dr. Dobak is also the founder of CryoGen, Inc., JAKK Group, Inc...
He currently holds the position of Chairman & Chief Executive Officer at 10xBio LLC and is a Member at San Diego YPO, Inc. In his former positions, Dr. Dobak served as President, Chief Executive Officer & Director at DermTech Operations, Inc. (2012-2019) and DermTech, Inc. (2019-2023).
He obtained an undergraduate degree from the University of California, Los Angeles and a doctorate degree from the University of California San Diego.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
DERMTECH, INC.
2,02% | 15/03/2023 | 698 693 ( 2,02% ) | 490 482 $ | 31/03/2024 |
Postes actifs de John D. Dobak
| Sociétés | Poste | Début |
|---|---|---|
| JAKK Group, Inc. | Founder | 11/03/2011 |
| San Diego YPO, Inc. | Corporate Officer/Principal | - |
10XBio LLC
 10XBio LLC BiotechnologyHealth Technology 10XBio LLC is an American biotechnology company that specializes in finding new uses for existing therapies and technologies. By leveraging known mechanisms of action and building on existing safety profiles, the private company is able to streamline the development and regulatory process. The company's most advanced asset, 10xb101, is a pharmaceutical product that addresses unmet needs in aesthetic medicine. The company's focus on repurposing existing therapies and technologies allows for accelerated development and a more efficient regulatory process. | Chief Executive Officer | - |
Anciens postes connus de John D. Dobak
| Sociétés | Poste | Fin |
|---|---|---|
| DERMTECH, INC. | Chief Executive Officer | 08/05/2023 |
DermTech Operations, Inc.
 DermTech Operations, Inc. Medical SpecialtiesHealth Technology DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA. | Chief Executive Officer | 01/08/2019 |
Neothetics, Inc.
 Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | Founder | 25/07/2014 |
Leptos Biomedical, Inc.
 Leptos Biomedical, Inc. Medical SpecialtiesHealth Technology Leptos is developing a proprietary neuromodulation therapy for chronic obesity. The treatment, delivered via a pacemaker-type device, involves electrical activation of a specific nerve in the autonomic nervous system. They believe that this therapy may offer an effective minimally invasive, reversible surgical option for people suffering from chronic obesity. As yet, the Leptos therapy is not approved for sale in the United States and is limited to investigational use. | Founder | 12/11/2010 |
CryoCor, Inc.
 CryoCor, Inc. Medical SpecialtiesHealth Technology CryoCor, Inc. provided medical technology services. It developed and manufactured a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The firm's product the CryoCor Cardiac Cryoablation System, was designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The company was founded in 2000 and was headquartered in San Diego, CA. | Founder | - |
Formation de John D. Dobak
| University of California, Los Angeles | Undergraduate Degree |
| University of California San Diego | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DERMTECH, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
CryoGen, Inc.
 CryoGen, Inc. Medical SpecialtiesHealth Technology CryoGen, Inc. develops medical products used in abnormal uterine bleeding | Health Technology |
CryoCor, Inc.
CryoCor, Inc. Medical SpecialtiesHealth Technology CryoCor, Inc. provided medical technology services. It developed and manufactured a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The firm's product the CryoCor Cardiac Cryoablation System, was designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The company was founded in 2000 and was headquartered in San Diego, CA. | Health Technology |
DermTech Operations, Inc.
DermTech Operations, Inc. Medical SpecialtiesHealth Technology DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA. | Health Technology |
Post-Hypothermia Corp.
 Post-Hypothermia Corp. Medical SpecialtiesHealth Technology Post-Hypothermia Corp. develops and provides temperature modulation therapy products for the healthcare industry. It also provides CoolBlue, a surface-based temperature modulation system that consists of a console and a disposable CoolBlue vest with upper thigh pads, which is designed for use in less acute patients or prolonged temperature management clinical settings. The company was founded by John D. Dobak in 1998 and is headquartered in San Diego, CA. | Health Technology |
Leptos Biomedical, Inc.
Leptos Biomedical, Inc. Medical SpecialtiesHealth Technology Leptos is developing a proprietary neuromodulation therapy for chronic obesity. The treatment, delivered via a pacemaker-type device, involves electrical activation of a specific nerve in the autonomic nervous system. They believe that this therapy may offer an effective minimally invasive, reversible surgical option for people suffering from chronic obesity. As yet, the Leptos therapy is not approved for sale in the United States and is limited to investigational use. | Health Technology |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | Health Technology |
| JAKK Group, Inc. | |
| San Diego YPO, Inc. | |
10XBio LLC
10XBio LLC BiotechnologyHealth Technology 10XBio LLC is an American biotechnology company that specializes in finding new uses for existing therapies and technologies. By leveraging known mechanisms of action and building on existing safety profiles, the private company is able to streamline the development and regulatory process. The company's most advanced asset, 10xb101, is a pharmaceutical product that addresses unmet needs in aesthetic medicine. The company's focus on repurposing existing therapies and technologies allows for accelerated development and a more efficient regulatory process. | Health Technology |
